Fred Alger Management, LLC Viridian Therapeutics, Inc.\De Transaction History

Fred Alger Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$22.57 - $29.67 $4.88 Million - $6.42 Million	-216,358 Reduced 66.84%	107,318 $2.55 Million
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $2.62 Million - $3.93 Million	-104,597 Reduced 24.42%	323,676 $8.23 Million
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $3.14 Million - $4.97 Million	167,190 Added 64.04%	428,273 $12.5 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $2.79 Million - $6.66 Million	261,083 New	261,083 $5.36 Million

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $839M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.